Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5258_Библиотеки_им_академика_М_И_Перельмана.pdf
491
testing, 291
Mycobacterial infections, 213, 214, 262
Mycophenolate, 33, 159, 176, 303
Mycophenolate mofetil (MMF), 140
Mycophenolic acid (MPA), 140, 176, 303
Myelodysplastic syndrome (MDS), 189
N
National Comprehensive Cancer Network
(NCCN), 402
Nausea, 456, 457
Necrotizing soft tissue infections (NSTIs), 243
Non-adherence to immunosuppressive
medications, 93
Non-HPV associated gynecologic cancers, 318
Non-infectious causes, 224
Non-infectious etiologies of fever, 437
Non-invasive imaging, 151
Non-ischemic cardiomyopathy, 162
Non-kidney solid organ transplant
(NKSOT), 340
Nonmelanoma skin cancer (NMSC),
282–284, 307
Nonsteroidal anti-inammatory drugs
(NSAIDs), 345, 455
Norovirus, 223, 277
Nutrition, 10–11, 126
O
Obesity, 126
Oncogenic infections, 305, 306
Oncology, 321
Opioid use disorder (OUD), 18, 373
Opioids, 454, 456
Optical coherence tomography (OCT), 153
OPTN Pediatric Transplantation
committee, 441
Oral glucose tolerance test (OGTT), 337, 338
Oral lesions, in SOT recipient, 225–228
Organ Procurement and Transplantation
Network (OPTN), 7
Organ-specic risk factors, 330
Osteoarthritis, 291
Osteopenia, 478
Osteoporosis, 289, 393, 478
epidemiology, 347
pathophysiology, 347, 348
prevention, 348
screening, 348
treatment, 349
Overall rejection surveillance strategies, 147
P
Pain management, 129, 455, 456
Palliative care, 447
ACP, 449
advance directive, 449, 450
challenges, 452
goals of care, 451
pre-transplant illness, 450
primary care assessment, 452
resources for, 453, 454
advance directive, 450
core principles, 447
symptom management, 454
depression and anxiety, 458
diarrhea, nausea, and constipation,
456, 457
dyspnea, cough, 456
edema, 457
pain, 455, 456
resources, 458, 459
transplant failure, 459, 460
Palliative care interventions, 448
Pancreas after kidney (PAK), 95, 96
Pancreas allograft dysfunction
clinical presentation and differential
diagnosis of, 99
monitoring and detection of, 99
Pancreas transplant alone (PTA), 95
Pancreas transplant recipients, 94, 95
acute rejection, 100
anatomy, 97
benets of, 96
eligibility criteria and pre-transplant
considerations for, 96, 97
immunosuppression, 97, 99
pancreas allograft dysfunction, clinical
presentation and differential
diagnosis of, 99
pancreas allograft dysfunction, monitoring
and detection of, 99
suspected acute rejection, workup for, 100
Parasites, 224
Parasitic, 277
Patient Health Questionnaire-9 (PHQ-9),
361, 458
PCSK9 inhibitors, 79
Pediatric kidney transplant recipients, 92, 93
Index
492
Pediatric Quality of Life Inventory (PedsQL)
Transplant Module, 439
Pediatric solid organ transplant recipient
adolescence, psychosocial impacts and
adherence, 439, 440
continuity care provider, 432, 433
development, 438, 439
fever and infection, 435
CMV, 436
EBV, 436, 437
non-infectious etiologies, 437
polyomaviruses, 437
growth and nutrition, 438
organ sharing number, United network
for, 432
post-transplant vaccination, 434, 435
survival rates of, 432
transition of care, 440, 441
vaccination, 433
Pericardium, 138, 139
Peripheral vascular disease (PVD), 97
Persistent hyperparathyroidism, 86
Phosphorus, 86
Pleura, 174
Pleural effusion, 268
Pneumococcal vaccine, 413
Pneumocystis jirovecii, 214, 260
Pneumocystis jirovecii pneumonia (PJP), 195
Pneumonia, 260
Polyomaviruses, 437
Portal vein thrombosis, 116
Post-transplant course, 451
Post-transplant diabetes mellitus (PTDM), 81,
331, 337
assessment of, 336
management, 339
pathophysiology, 337
screening, 338
Post-transplant erythrocytosis (PTE), 90
Post-transplant lymphoproliferative disorder
(PTLD), 84, 164, 189, 279, 308,
403, 437
epidemiology, 309
pathophysiology and classication, 309
presentation, 310, 311
prevention, 312
prognosis, 312
risk factors, 310
treatment, 311, 312
Post-transplant malignancies, 83–85
Post-transplant vaccination, 434, 435
Post-traumatic stress disorder (PTSD), 359,
420, 439
Potassium-sparing diuretics, 89
Pre-conception counseling, 382
cytomegalovirus infection prevention,
385, 386
medical evaluation prior to
pregnancy, 383
medication management, 383–385
pregnancy timing, 382
Prednisone, 34
Pregnancy, 50–51
heart transplant recipient, 159
and sexual health, 93, 94
SOT, 390, 391
Pre-transplant course, 451
kidney transplant recipients, 56
allocation, 58
indication for, 56, 57
treatment, 57
waiting list, 57
Pre-transplant diabetes, 335
Pre-transplant evaluation, solid organ
transplantation, 8, 9
cancer screening, 15
cardiopulmonary screening, 10
dental evaluation, 11
family planning, 12
nancial evaluation, 17
functional status, nutrition and bone
density, 10, 11
history and examination, 9
infections, 14, 15
laboratory testing, 9, 10
medication adherence, 17
organ-specic testing, 12
psychiatric evaluation, 17
psychosocial evaluation, 16
substance use, 18
surgical evaluation, 16
vaccines and pre-transplant
prophylaxis, 12–14
Pretransplant malignancy (PTM), 320
Pre-transplant mental health
pharmacology considerations, 358
prevalence of affective disorders, 356
primary care, 358
psychosocial and mental health screening,
356, 357
substance use disorders, prevalence and
screening, 357, 358
Index
493
Pre-transplant prophylaxis, 12–14
Primary care physicians, 417, 422
Primary care provider (PCP), 329, 431, 433,
438, 440, 448, 451
Primary palliative care, 447
Probenecid, 346
Progestin only pills (POP), 387
Progressive multifocal leukoencephalopathy
(PML), 238
Prostate cancer, 319
Psychosocial development, 365
Psychotherapy, 458
PTSD CheckList Civilian Version
(PCL-C), 361
Pulmonary tuberculosis, 262
Pyelonephritis, 230, 233
Q
Quality of life, 431, 451
R
Recurrent urinary tract infection, 234
Rejection surveillance
antibody-mediated rejection, 144, 146, 147
cellular rejection, 145, 146
Renal cell carcinoma (RCCs), 83
Renal disease, 187
Respiratory infections, SOT, 198–216
diagnostic considerations, 200, 205
respiratory viral illnesses, 206–215
Respiratory syncytial virus (RSV), 211,
413, 415
Respiratory viral illnesses
bacterial pneumonia, 212, 213
fungal pneumonia, 214, 215
herpes viruses, 211, 212
inuenza
clinical presentation, 208
diagnosis, 208
prevention, 210, 211
treatment, 209, 210
mycobacterial infections, 213, 214
RSV, 211
severe acute respiratory syndrome
coronavirus 2, 206
clinical presentation, 206
prevention, 207, 208
treatment, 206, 207
Respiratory viral infections, 211–212
Respiratory viruses, 181
Right anterior oblique (RAO), 150
Risk Evaluation and Mitigation Strategies
(REMS) program, 388
S
Salmonella enterica serovar Typhi, 418
Sapovirus, 223–224
SARS-CoV-2 vaccine, 383
Selective serotonin reuptake inhibitor (SSRI),
371–372, 458
Serious mental illness (SMI), 374
Serotonin-norepinephrine reuptake inhibitors
(SNRIs), 372
Sertraline Antidepressant Heart-Attack
Randomized Trial
(SADHART), 372
Severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2), 206
clinical presentation, 206
prevention, 207, 208
treatment, 206, 207
Sex hormones, 467
Sexual health, 93–94
Sexually transmitted infections (STIs),
234, 245–247
Simultaneous pancreas-kidney (SPK),
95, 96, 100
Sirolimus, 35, 304, 331, 338, 341
Skin and lip cancer, 307, 308
Skin and soft tissue infections
(SSTIs), 239–247
cellulitis and abscesses, 241–243
diagnostic considerations, 240, 241
infectious nodular and ulcerative lesions,
244, 245
infectious vesicular eruptions, 243, 244
necrotizing soft tissue infections, 243
sexually transmitted infections, 245, 246
Skin and Ultraviolet Neoplasia Transplant
Risk Assessment Calculator
(SUNTRAC), 399
Skin cancer, 83, 188, 282, 398, 399
Small intestine bacterial overgrowth
(SIBO), 279
Smoking, 18, 185
Sodium-glucose cotransporter-2 inhibitors
(SGLT2 inhibitors), 82, 339, 342
Index
494
Solid organ transplantation (SOT), 193, 257,
299, 329
cancers associated with increased risk, 306
colorectal cancer, 317, 318
donor transmitted cancer, 306
head and neck cancer, 315, 316
hepatobiliary cancer, 316, 317
HPV-associated cancer, 314, 315
Kaposi’s sarcoma, 318
kidney and urothelial cancers, 313, 314
lung cancer, 312, 313
PTLD, 308–312
skin and lip cancer, 307, 308
thyroid cancer, 316
cancer screening and prevention
pre- transplantation, 319, 320
cancers, types of, 301
cancers without an apparent de novo
increased risk
breast cancer, 318, 319
non-HPV associated gynecologic
cancers, 318
prostate cancer, 319
communication with transplant
specialists, 24, 25
complications, 22
constitutional symptoms, 292
dermatologic issues in, 282
cosmesis, 288
graft-versus-host disease, 287
infection, 286
Kaposi sarcoma, 285
malignancy, 282
melanoma, 284
Merkel cell carcinoma, 286
non-melanoma skin cancers, 282–284
diagnostic approach, 198
epidemiology
cancer incidence, 299, 300
cancer mortality, 300, 301
timing, 301
examination, 23
follow-up plan, 24
gastrointestinal infections, 216–228
parasites, 224
Clostridioides difcile, 217, 219–221
cytomegalovirus, 221–223
diagnostic considerations, 217, 218
esophagitis, 225
norovirus, sapovirus and astrovirus,
223, 224
oral lesions, 225, 228
non-infectious causes, 224
graft function, 22
immunosuppression and related infection
risk, 194
early post-transplant period, 194
intermediate post-transplant
period, 194–196
late post-transplant period, 197
implications of, 7
infections of the central nervous
system, 235–239
bacterial infections, 237
diagnostic considerations, 236, 237
fungal infections, 236, 238
viral infections, 237, 238
medications, 23
metabolic complications, 23
multidisciplinary cancer centers for,
321, 322
musculoskeletal symptoms, 288–291
pre-transplant evaluation, 8, 9
cancer screening, 15
cardiopulmonary screening, 10
dental evaluation, 11
family planning, 12
nancial evaluation, 17
functional status, nutrition and bone
density, 10, 11
history and examination, 9
infections, 14, 15
laboratory testing, 9, 10
medication adherence, 17
organ-specic testing, 12
psychiatric evaluation, 17
psychosocial evaluation, 16
substance use, 18
surgical evaluation, 16
vaccines and pre-transplant
prophylaxis, 12–14
prevalence, 5
prevention, 247
primary care, 1
primary care roles, 2
primary care, returning to, 19
respiratory infections, 198–216
diagnostic considerations, 200, 205
respiratory viral illnesses, 206–215
respiratory symptoms, 258
cough, 258–265
dyspnea, 265–269
risk factors, 301
age, 302
Index
495
gender, 303
immunosuppression, 303, 304
medical conditions and behaviors, 305
oncogenic infections, 305, 306
type of transplant, 304
screening and prevention
post- transplantation, 320
serologic status, 23
skin and soft tissue infections, 239–247
cellulitis and abscesses, 241–243
diagnostic considerations, 240, 241
infectious nodular and ulcerative
lesions, 244, 245
infectious vesicular eruptions, 243, 244
necrotizing soft tissue infections, 243
sexually transmitted infections,
245, 246
time course, 21, 22
timeline for infection risk, 195
transplant history, 19, 21
transplanted organ, 21
trends in, 6
in United States, 6, 7
urinary symptoms, 270
clinical stability, 270
diarrhea, 273–281
differential diagnosis, 271, 272
examination, 271
history, 270, 271
non-infectious, 272
testing and treatment, 272
urinary tract infections, 228–235
Carbapenem-resistant Klebsiella
pneumoniae, 231, 232
complications and outcomes, 231
denitions, 229
diagnostic considerations, 232
risk factors, 230, 231
sexually transmitted infections, 234
therapeutic considerations, 233
treatment recommendations by
condition, 233, 234
waiting for, 18, 19
Spironolactone, 472, 473
Squamous cell carcinoma (SCC), 188, 398
Standardized incidence ratio (SIR), 189, 300
Standard three-drug regimen, 63
Stanford Integrated Psychosocial Assessment
for Transplant (SIPAT), 356–358
Statin therapy, 334
Statins, 157
Stenosis, 116
Steroid withdrawal, 82
Substance use, 18, 185
Substance use disorders
behavioral and, pharmacologic
management of, 373, 374
DSM-V diagnostic criteria, 363
post liver transplant, prevalence and impact
of,
361, 362
post liver transplant, screening, 362, 363
prior to liver transplant, 357, 358
Supraventricular tachycardias (SVTs), 153
Surveillance bronchoscopy, 177–178
Symptom management, 454
depression and anxiety, 458
diarrhea, nausea, and constipation,
456, 457
dyspnea, cough, 456
edema, 457
pain, 455, 456
Systemic hypertension, 127
T
Tacrolimus, 32, 64, 143, 341, 344
Tacrolimus monotherapy, 143
Testosterone, 475, 476
Thiazide-type diuretics, 80
Thiazolidinediones (TZDs), 339
Thrombocytopenia, 90
Thyroid cancer, 316
Tobacco, 18
Topical estrogens, 78
Transbronchial biopsies (TBBX), 179
Transfeminine, 468
Transgender, 465, 466
Transient hyperglycemia, 335
Transition of care, 440, 441
Transmasculine, 468
Transplant centers, 182
Transplant failure, 459, 460
Transplant medications, 405
Transplant medicine, 1
Transplant recipients, 455
Transplanted organ, 21
Trimethoprim-sulfamethoxazole (TMP-SMX),
215, 333
U
Ulcerative l, 244–245
United Network for Organ Sharing (UNOS), 5
Upper respiratory tract infections, 262
Index
496
Urate lowering therapy, 346
Urinary tract infection (UTI), 76–78, 228–235
Carbapenem-resistant Klebsiella
pneumoniae, 231, 232
complications and outcomes, 231
denitions, 229
diagnostic considerations, 232
risk factors, 230, 231
sexually transmitted infections, 234
therapeutic considerations, 233
treatment recommendations by condition,
233, 234
Urine leak, 72
Urothelial cancers, 313–314
US Advisory Committee on Immunization
Practices (ACIP), 413
US Preventive Services Task Force
(USPSTF), 399
V
Vaccination, 433
Vaccines, 12–14
Valvular heart disease, 154
Vascular anastomosis, 134
Vascular complications, 72, 116
Venous thromboembolism, 470
Viral hepatitis, 120
Viral infections, 262
Viral infections of the CNS, 237–238
Vitamin D, 87
W
Waterborne infections, 416
Weight gain, 82, 83
World Health Organization (WHO), 413
Z
Zoster vaccine, 414
Index